Moventia has renewed its partnership with the FERO Foundation, a leader in cancer research, reaffirming its commitment to initiatives that make a real difference in people’s lives. Spanning 2024 to 2026, this collaboration highlights Moventia’s dedication to improving cancer care and advancing cutting-edge research.

Through this three-year agreement, Moventia will continue to support the FERO Foundation’s Advanced Molecular Diagnostics (DIAMAV) programme. Led by Susana Aguilar, head of VHIOTECA, this initiative brings together expertise from the Oncology Data Science Group (ODysSey), the Cancer Genomics Group, the Molecular Oncology Group, the Cancer Molecular Therapy Research Unit (UITM) – CaixaResearch and the Early Drug Development Group at the Vall d’Hebron Institute of Oncology (VHIO). Funded by the Foundation for over five years, DIAMAV focuses on identifying key molecular changes driving tumour development, enabling personalised treatments and expanding access to clinical trials for targeted therapies.

This renewed partnership reflects Moventia’s broader vision of corporate social responsibility—going beyond mobility to champion innovation and create a lasting, positive impact on society.

Moventia and the FERO Foundation have been working together since August 2019, uniting their expertise in mobility and cancer research to become strong allies in the fight against cancer.